What Happens When Your Doctor Lowers Your Psychiatric Med?Why the pace matters more than almost anyone realizes
Most prescribers taper medication in good faith, using the doses their patients can actually buy. But commercially available tablets often step down far too steeply near the end — and the person left holding those symptoms is frequently sitting in a therapist’s office, not a physician’s.
Read-aloud is not available in this browser. Chrome, Edge, and Safari support it.
Never change your dose on your own
Do not stop, skip, split, or reduce any psychiatric medication without talking to your prescriber first. Stopping some medications suddenly is not merely uncomfortable — it can cause seizures, severe psychiatric symptoms, and other medical emergencies. This page exists to help you have a better conversation with your prescriber and pharmacist. It is education, not a tapering plan, and it is not a substitute for medical care.
If you are having thoughts of harming yourself, call or text 988 (Suicide & Crisis Lifeline) or go to your nearest emergency room. Thoughts of self-harm can emerge during medication changes even in people who have never had them before.
A note on my role: I do not prescribe, and nothing here is a medication recommendation
Wodzenski
I am a Licensed Professional Counselor. I do not prescribe medication, and I do not make recommendations about whether, when, or how any person should change a dose. Those decisions belong entirely to your prescribing provider.
I share this information from my role as a clinical mental health provider who supports clients as they navigate medication changes that their prescribers have implemented. My work is to help you notice what is happening, describe it accurately to the people who do prescribe, and stay steady while your system adjusts.
I also encourage every client to recruit the wisdom and insight of a pharmacist as part of an integrated care team. Pharmacists hold detailed knowledge about formulations, dosage forms, and compounding options that is often the missing piece in these conversations, and they are consulted far less often than they should be.
What I see in my office
A client is doing well. Their prescriber agrees it may be time to come off a medication. The taper is described as gradual — cut the dose in half, then in half again, then stop. On paper it looks careful.
Three weeks later that client is in my office describing electrical sensations in their head, waves of dread that arrive without cause, sleep that has fallen apart, and a sense that something is fundamentally wrong that they cannot put into words. They have often already been told this is their original condition returning.
Sometimes it is. Frequently it is not.
I have supported many people through significant distress on a schedule that both the prescribing provider and the pharmacist considered entirely routine. That is worth sitting with. Nobody was careless. The schedule was ordinary. It was simply wrong for that person, and there was no way to know in advance except by watching closely and adjusting.
Therapists occupy a particular vantage point here. We see clients weekly, often for an hour, and we know their baseline in fine detail — how they normally speak, sleep, think, and regulate. When something shifts, we notice it early, and we hear about it in far more detail than a fifteen-minute medication check allows. That is not a criticism of prescribers. It is a description of two different sightlines onto the same person, and it is exactly why the two need to be connected.
If you are planning a change — or already struggling with one
Whether you are considering coming off a medication, are partway through a taper that has become harder than expected, or are trying to work out whether what you are feeling is withdrawal or something else, you do not have to sort it out alone.
MS ESE, MA CMHC, PhD, LPC, ACS
Prefer to text? That is completely fine — many people find it easier to start that way. Please do not include detailed health information in a text or email, as neither is a secure channel.
If you are in crisis, call or text 988 or go to your nearest emergency room. For a medical emergency, call 911.
Two terms worth knowing
Having accurate language changes what you can ask for. These are the terms your prescriber and pharmacist will recognize.
Hyperbolic tapering
Also called the Horowitz–Taylor method, after the two researchers who described it. Rather than removing the same number of milligrams at each step, each reduction is a percentage of the current dose — so the steps get progressively smaller as the dose gets lower (Horowitz & Taylor, 2019).
The related umbrella terms are deprescribing (the planned, supervised reduction or discontinuation of a medication) and gradual dose reduction. Refinements you may hear include microtapering (very small daily reductions), cut-and-hold (reduce, then stay put until symptoms settle), and personalised tapering — an individualised schedule that is flexibly adapted as the person responds, rather than fixed in advance (Groot & van Os, 2021).
One term deserves its own mention: stabilisation. This means deliberately staying at the current dose — not going back up, not going down — when withdrawal symptoms appear, giving the person time to settle before the taper resumes. Stabilisation is a planned clinical step, not a failure of the taper, and it is one of the most useful things to agree on with your prescriber before you begin.
Precisely stated: hyperbolic tapering of the dose is what produces a steady, linear reduction in receptor occupancy. Linear tapering of the dose does the opposite — it produces an increasingly steep drop in occupancy as the dose falls (Groot & van Os, 2021; Horowitz & Taylor, 2019).
This is now more than a fringe position. Britain’s National Institute for Health and Care Excellence revised its guidance to recommend proportional rather than linear reductions (NICE, 2022a, 2022b).
Abrupt discontinuation and over-rapid tapering
Abrupt discontinuation is stopping outright. Over-rapid tapering is reducing faster than the nervous system can adapt — which is far more common, and much easier to miss, because it looks like a taper.
What follows is called a withdrawal syndrome or, for antidepressants specifically, antidepressant discontinuation syndrome — a label many researchers now consider misleadingly gentle. Chouinard and Chouinard (2015) separate three distinct patterns:
- New withdrawal symptoms — symptoms the person never had before, caused by the dose change itself.
- Rebound — the original symptoms returning rapidly and more intensely than before treatment.
- Persistent post-withdrawal disorder — symptoms lasting well beyond the expected window.
When symptoms continue for months or longer, you may hear protracted withdrawal syndrome. Drug-specific forms have their own names: supersensitivity psychosis and withdrawal dyskinesia after antipsychotics, cholinergic rebound syndrome after certain antipsychotics and tricyclics, and rebound mania after mood stabilizers.
Why “just cut it in half” stops working near the end
This is the part that most often surprises people, including clinicians.
The relationship between the dose of a medication and its effect at the brain’s receptors is not a straight line. It is a curve. At higher doses, receptors are already close to fully occupied — so a large reduction in milligrams produces only a small change in what the brain actually experiences. At low doses, the curve turns sharply, and the same small reduction in milligrams produces a very large change (Sørensen et al., 2022).
This is why so many people sail through the first several reductions and then fall apart on the final step. That last step, which looks like the smallest one on paper, is often the biggest one the brain has been asked to absorb.
If you find diagrams helpful, there is one at the very bottom of this page showing exactly this. If you do not, you can skip it entirely — the paragraph above is the whole idea.
But this is not only an end-of-taper problem. Where a given person sits on that curve depends on their own physiology, and for some the bend arrives much earlier than expected — which is why difficulty at the first reduction is common and should never be dismissed as anxiety about the process.
It also explains a pattern I hear constantly: “I did fine going from 40 to 20 to 10, so I don’t understand why 10 to zero destroyed me.” Nothing went wrong with the person. The arithmetic was wrong.
There is no such thing as a typical taper
Standard schedules exist because clinicians need somewhere to start, and most people do reasonably well on them. But the rate at which a nervous system can adapt varies enormously between individuals, and there is currently no test that predicts it in advance.
This means that a person struggling badly on a routine schedule is not failing at it, and is not overreacting. They are giving you the only information anyone was ever going to get — that this pace does not suit them. The correct response is to adjust the pace, not to question the person.
Hyperbolic — steps shrink
- Each reduction is a percentage of the current dose, so steps get smaller as the dose falls.
- Keeps each step roughly equivalent in what the brain experiences.
- Pace is set by how the person responds, not by the calendar.
- The taper can pause, or step back up, when symptoms appear.
- Often takes many months. Sometimes longer.
Linear — steps stay the same
- The same number of milligrams comes off at every step.
- Feels easy early, then becomes disproportionately hard.
- Pace is set by available tablet sizes and appointment schedules.
- Symptoms near the end are frequently read as relapse.
- Often compressed into a few weeks.
When the available doses are too far apart
Here is the bind prescribers are in. A medication may be manufactured only as a 20 mg and a 10 mg tablet. If a person needs to step down by small increments below 10 mg, the pharmacy simply does not stock what they need. The prescriber is not being careless — the dosage forms do not exist.
Ways to create the steps that aren’t on the shelf
These are options to raise with your prescriber and pharmacist — never to arrange on your own. Which ones are appropriate depends entirely on the specific medication.
- Compounded formulations. A compounding pharmacy can prepare doses between commercial strengths — often needed only for the few weeks it takes to bridge one difficult gap. See the note below on how to raise this.
- Liquid preparations. Some medications come in a manufactured liquid, which allows precise small reductions. Some liquids can be further diluted; a pharmacist must advise on this.
- Tapering strips. Daily pouches, each holding the same or a slightly lower dose than the last, developed specifically for gradual reduction (Groot & van Os, 2020).
- Tablet splitting. Useful early on, but only for medications that can be safely split, and it loses precision at very small doses.
Your pharmacist is the most underused person on your care team. They know which formulations exist, which tablets can be split, which have coatings that must not be broken, whether a compounding pharmacy nearby can help, and what your insurance will cover. Many are glad to be asked and rarely are.
The bridge dose — the question I most often suggest clients ask
When a client tells me the next step down looks too big, the specific thing I encourage them to raise with their prescriber and pharmacist is narrow and practical: could a compounded dose somewhere between the two commercially available strengths be prepared, for a brief period, just long enough to turn one large leap into two or three manageable steps?
I want to be precise about what I am and am not doing here. I am not recommending a dose, a schedule, or a formulation — I am not qualified to, and it would be outside my scope. I am suggesting that a client ask a question that they may not know is available to ask, and that their prescriber and pharmacist then decide together whether it fits their situation.
Framing it this way tends to work better than a general request, for three reasons.
- It is time-limited. Most people do not need compounded medication for an entire taper — only across the one or two gaps their system cannot absorb. A brief bridge keeps the cost, the inconvenience, and the departure from routine practice contained.
- It is concrete. “Could we go slower?” often ends the conversation, because slower is not possible with the tablets on the shelf. “Could we bridge this particular gap with a compounded dose for a few weeks?” is a request a prescriber can actually act on.
- It brings the pharmacist in. Whether a given medication can be compounded, at what strengths, and how stable the preparation is, are pharmacy questions. Asking the question this way naturally recruits the person best equipped to answer it.
The goal is not to slow everything down indefinitely. It is to approximate a more conservative, hyperbolic reduction using what is actually obtainable — closing the distance between the taper that would suit this person’s nervous system and the taper the available dosage forms permit.
Not every medication can be compounded or divided
Extended-release, delayed-release, and enteric-coated formulations are generally not candidates. The coating or matrix is the medication’s release mechanism, and breaking it can deliver the entire dose at once instead of over hours. Some medications are also chemically unstable outside their manufactured form, and some have no suitable compounding base.
Occasionally the answer is that a prescriber will switch a person to an equivalent immediate-release or liquid version first, precisely because it can be divided more finely. That is a clinical decision requiring the prescriber’s judgment and the pharmacist’s input — never something to attempt independently.
Compounded preparations are also not FDA-approved products in the way manufactured tablets are, and they are often not covered by insurance. A brief bridge keeps that cost manageable; an open-ended one may not be.
When the right doses are available, most people can do it
Groot and van Os (2021) followed 824 people in the Netherlands who used tapering strips to come off an antidepressant. This was not an easy group: the median duration of use was five to ten years, and 71% had already tried to stop at least once and failed.
72% discontinued successfully, using a median of two strips over a median of 56 days. Participants rated their withdrawal as far milder with the strips than in their previous attempts — a median severity of 3 out of 7, against 6 out of 7 without them. This was the third independent study to reach essentially the same result.
Two findings worth carrying into your own conversation:
- Longer use makes tapering harder. 78% succeeded among those taking the medication under a year, compared with 59% among those taking it more than ten years. Length of use was the most consistently replicated risk factor.
- Half-life is not the whole story. Fluoxetine is often described as low-risk because it leaves the body slowly, yet participants coming off it reported the same median withdrawal severity as those coming off paroxetine or venlafaxine.
Note also how these patients found out about the option: fewer than 40% heard about it from a clinician, and the single most common source was the internet. That is not a criticism of prescribers — surveys find that only a small minority of general practitioners feel adequately informed about withdrawal management (Read et al., 2020). It is a gap in professional training, and it is precisely why bringing a written request to your appointment can help.
Skipping doses is not the same as lowering the dose
Taking a medication every other day to “average it out” seems logical, but for medications that clear the body within about a day, it produces sharp peaks and troughs in blood level rather than a steady lower level. Modelling work indicates this pattern risks more severe withdrawal than a steady reduction would (Horowitz & Taylor, 2024; Horowitz et al., 2025). If someone suggests alternate-day dosing, it is a reasonable thing to ask your prescriber and pharmacist about specifically.
Symptoms by medication class
Withdrawal looks different depending on what is being reduced. Expand each class below. This is not a complete list, and any new or worsening symptom during a dose change is worth reporting to your prescriber promptly.
Antidepressants — SSRIs, SNRIs, tricyclics
Withdrawal is common and frequently underestimated. A systematic review found that roughly half of people report withdrawal effects when coming off antidepressants, and among those, nearly half describe the experience as severe (Davies & Read, 2019). Shorter-acting medications such as paroxetine and venlafaxine tend to produce more intense effects.
The sensory symptoms are distinctive. “Brain zaps” — brief electrical-shock sensations in the head, often triggered by eye movement — are so characteristic that they are one of the clearest signals distinguishing withdrawal from a returning mood episode.
Benzodiazepines & Z-drugs — highest medical risk
Stopping a benzodiazepine abruptly can cause seizures, which can be fatal. The U.S. Food and Drug Administration (2020) requires a boxed warning stating that stopping suddenly or reducing too quickly can produce life-threatening withdrawal reactions, including seizures. Physical dependence can develop within days to weeks of regular use, even exactly as prescribed. Never stop a benzodiazepine on your own.
The FDA’s own case review found the median duration of withdrawal symptoms was around nine and a half months, with the longest documented case still ongoing after eight years. Withdrawal seizures have been reported even after short courses at ordinary therapeutic doses.
Benzodiazepine tapers are typically measured in many months, and complete discontinuation after long-term use often takes a year or more.
Antipsychotics — including for non-psychotic uses
Long-term blockade of dopamine receptors leads the brain to compensate by increasing receptor sensitivity. When the medication is removed suddenly, ordinary levels of dopamine can overstimulate those sensitized receptors — producing supersensitivity psychosis, a rapid-onset psychotic reaction that can occur even in people with no history of psychosis (Chouinard et al., 2017; Moncrieff, 2006).
Abrupt withdrawal has also been associated with movement disorders that resemble the ones antipsychotics are meant to treat — withdrawal dyskinesias, parkinsonian symptoms, and dystonias (Howland, 2010). Gradual, hyperbolic reduction is now the recommended approach (Horowitz et al., 2021).
This matters for a wider group than people often assume, since antipsychotics are frequently prescribed at low doses for sleep, anxiety, or mood — and those patients are often told the medication is minor enough to simply stop.
Mood stabilizers — lithium, anticonvulsants
Lithium was long assumed to carry no withdrawal risk. That assumption did not survive study. Rapid discontinuation is associated with rebound mania occurring sooner and more often than the natural course of the illness would predict, and relapse has been documented after stopping for only a few days (Baldessarini et al., 1996).
Discontinuing lithium — particularly abruptly — has been associated with increased suicidal behavior (Baldessarini et al., 2019). Any change to lithium warrants close coordination among prescriber, therapist, and family, and gradual reduction whenever it is possible.
Stimulants — ADHD medications
Stopping stimulants tends to produce a crash — a period of pronounced fatigue, low mood, and increased appetite as the nervous system readjusts. This is generally less medically dangerous than benzodiazepine or antipsychotic withdrawal, but it can be mistaken for a depressive episode and can be genuinely destabilizing, particularly for someone whose daily functioning has been organized around the medication.
Gabapentinoids — gabapentin, pregabalin
Often described to patients as carrying little withdrawal risk, these medications are now included in deprescribing guidance alongside antidepressants and benzodiazepines (Horowitz & Taylor, 2024). Abrupt cessation after sustained use can produce a withdrawal syndrome that overlaps considerably with benzodiazepine withdrawal.
Two symptoms that need urgent attention
Emerging thoughts of suicide or death. These can appear during a medication change even in someone with no prior history of them. This is not a sign of weakness or of the taper being “worth pushing through.” It is a signal to contact your prescriber immediately.
Akathisia — an intense inner restlessness, an inability to sit still, a feeling of being driven from the inside. It is frequently misread as anxiety or agitated depression, and it is deeply distressing. It warrants prompt medical attention rather than watchful waiting.
When withdrawal starts generating symptoms of its own
This is one of the most consequential things I see, and it is rarely explained to clients in advance.
When a dose comes down too quickly, two things commonly happen. Old symptoms the person thought were behind them return, sometimes more intensely than before. Or symptoms appear that they have never had in their life. Either way, the natural conclusion — for the client, and often for everyone around them — is that a mental health condition has come back or a new one has arrived.
Frequently, neither is true. What is present is a withdrawal phenomenon, and Chouinard and Chouinard (2015) name both patterns explicitly: rebound, where the original symptoms return in amplified form, and new withdrawal symptoms, which the person has never experienced before and which are caused by the dose change itself.
But there is a further step that makes this considerably harder to untangle, and it is the part I most want prescribers and families to understand.
Withdrawal interferes with the basics — and the basics hold mental health together
Lowering a dose too quickly does not only produce symptoms directly. It disrupts ordinary activities of daily living, and the two it disrupts most reliably are sleeping and eating.
Those two disruptions are not minor inconveniences alongside the withdrawal. They generate psychiatric symptoms in their own right, in anyone, regardless of diagnosis.
Sleep. Sustained sleep loss produces perceptual disturbances that progress, with increasing time awake, toward frankly psychotic phenomena — and this occurs in people with no psychiatric history whatsoever (Waters et al., 2018). A client several weeks into badly disrupted sleep can present with symptoms that look alarming and are, in fact, a consequence of not sleeping.
Nutrition. When nausea, appetite loss, or sheer exhaustion interrupt eating, mental health follows. The Minnesota Starvation Experiment demonstrated this definitively in healthy young men: sustained undernutrition produced depression, irritability, apathy, social withdrawal, and obsessive preoccupation — none of which had been present beforehand, all of which resolved with refeeding (Keys et al., 1950).
So a person can arrive at an appointment with genuine, severe, visible psychiatric symptoms that have three layers of cause — the withdrawal itself, the sleep loss the withdrawal caused, and the nutritional disruption the withdrawal caused — and not one of those layers is the condition the medication was originally prescribed for.
How the cascade runs
Before anyone concludes the condition has returned
When new or worsening symptoms appear during a taper, these are worth establishing before a diagnostic conclusion is drawn:
- How much has this person actually slept in the past week — not how much they were in bed, but how much they slept?
- How much have they actually eaten, and when did that change relative to the last dose reduction?
- Which came first — the psychiatric symptoms, or the sleep and appetite disruption?
- Did any of this exist before the dose changed?
This is straightforward information, and it is often decisive. It is also exactly the kind of detail that does not surface in a brief medication appointment, and does surface in an hour of conversation with someone who knows the person’s baseline.
Protecting the foundation
The cascade described above runs in one direction. It can also be run in the other.
What I do when I suspect the sleep is driving the symptoms
When I suspect that a client’s psychosis or mania is arising from sleep deprivation rather than from their underlying condition, I do not keep that observation to myself and I do not act on it alone. I raise it with the treating team and with the client, together, so that the prescriber has the week-to-week detail I have and the client hears the reasoning rather than being managed around.
What I then encourage is a slow, hyperbolic lowering of the dose while actively supporting sleep, good nutrition, exposure to sunlight, exercise, and socialization. Not the taper alone, and not the lifestyle measures alone — both, deliberately, at the same time.
In my experience, this is the difference-maker. When we promote healthy activities of daily living, clients tend to thrive through changes in even long-standing medications. The same reduction that destabilizes a person whose sleep has collapsed and who has stopped eating can be entirely manageable for that same person when those foundations are held steady.
This is also, frankly, work that suits a therapist’s role. I cannot adjust anyone’s dose. I can help someone protect their sleep, restore a routine, get outside in the morning, keep eating, and stay connected to people — and those turn out to matter enormously.
Sleep
The first priority, because sleep loss independently generates the symptoms most likely to be mistaken for relapse. Sleep reduction has been described as a final common pathway into mania (Wehr et al., 1987), and disrupted circadian rhythm is closely tied to mood instability (Harvey, 2008).
- Consistent wake time, even after a bad night
- Report sleep disruption to the prescriber early, not after weeks
- Track actual sleep, not time in bed
Nutrition
Withdrawal nausea and exhaustion quietly interrupt eating, and undernutrition produces depression, irritability, and apathy in anyone (Keys et al., 1950). Dietary improvement has shown benefit for depressive symptoms in controlled trial (Jacka et al., 2017).
- Regular meals, even small ones, over appetite-led eating
- Protein and steady intake through the difficult stretch
- Flag persistent nausea to the prescriber
Sunlight
Morning light exposure is the strongest signal for anchoring the circadian clock, which in turn stabilizes sleep. This is a small daily action with an outsized effect on the pillar that matters most.
- Outdoors early, ideally within an hour of waking
- Daylight beats indoor lighting by orders of magnitude
- Even overcast days carry the signal
Exercise
Movement supports sleep, appetite, and mood simultaneously, and has meta-analytic support as a treatment for depression in its own right (Schuch et al., 2016). During a taper, consistency matters more than intensity.
- Gentle and regular beats occasional and hard
- Walking counts
- Scale back on bad days rather than stopping
Socialization
Contact with people regulates daily rhythm and interrupts the withdrawal into isolation that withdrawal symptoms encourage. Structured attention to social rhythms has improved outcomes in mood disorder (Frank et al., 2005).
- Keep low-demand contact on the calendar
- Tell one or two people what you are going through
- Isolation is often the first thing to slip and the last to be noticed
Held together
None of these is remarkable on its own. That is rather the point — they are ordinary, unglamorous, and frequently the first things to be abandoned when someone feels unwell.
Protected deliberately, and alongside a pace the nervous system can absorb, they are what allow people to come through changes to medications they have taken for years.
These support medical care. They do not replace it.
If psychosis, mania, or severe symptoms are present, that is a situation for the prescribing provider, urgently, and sometimes for emergency care. Supporting sleep, nutrition, light, movement, and connection is what runs alongside appropriate medical attention and a suitably paced taper — never instead of it.
Nothing here should be read as suggesting that a person can manage a serious psychiatric emergency with routine and sunlight. The argument is narrower: that these foundations are frequently overlooked during medication changes, that their collapse generates symptoms of its own, and that protecting them deliberately changes how well people tolerate a taper.
Withdrawal or relapse?
This is the question that determines what happens next, and getting it wrong has real consequences in both directions. Withdrawal mistaken for relapse leads to medication being restarted or increased unnecessarily — and to a person concluding they will need medication for life. Relapse mistaken for withdrawal leads to a genuine episode going untreated.
Neither error is trivial. Horowitz and Taylor (2022) identify several features that help distinguish them, and this is precisely where a therapist who knows the client well can contribute something a chart review cannot.
If you have had the experience of describing withdrawal symptoms and being told they were something else, you are not unusual. In a survey of patients reporting antidepressant withdrawal, Guy et al. (2020) found that people were frequently dismissed outright, told their original condition had returned, or investigated for a new and unrelated medical problem. Naming this pattern is not an accusation against any individual prescriber — it is a well-documented gap, and knowing about it makes it easier to raise the question directly and without apology.
Points toward withdrawal
- Onset within days of a dose change
- Physical symptoms — dizziness, brain zaps, nausea, flu-like aching — that were not part of the original condition
- Symptoms the person has never experienced before
- Rapid improvement if the dose is restored
- Symptoms that fluctuate through the day in waves
Points toward relapse
- Onset weeks to months after the change, not days
- Symptoms that match the person’s own previous episodes
- Gradual build rather than sudden arrival
- Absence of the distinctive physical symptoms
- A course that follows the person’s known illness pattern
Your prescriber knows the pharmacology. You know how this feels. Your therapist knows what you looked and sounded like six weeks ago, and can often say with real precision whether this resembles your previous episodes or is something categorically different. That third data point frequently settles the question — but only if someone thinks to ask for it.
People have been saying this for years
These accounts are not unusual, and the volume of them is part of what shifted clinical guidance.
In April 2018, The New York Times published an investigation into people who found themselves unable to stop taking antidepressants, and invited readers to write in about their own experiences. More than 8,800 people responded — teenagers, students, new mothers, people in retirement. Some wrote to say the medications had saved their lives and objected to the framing. Many others described symptoms lasting far longer than anyone had prepared them for.
Carey & Gebeloff, 2018; The New York Times, 2018
The peer support community Surviving Antidepressants was founded by a woman who spent roughly seven years working her way through withdrawal largely without informed medical guidance. The site now hosts thousands of people comparing notes on tapering — and in interviews, researchers have noted that patients were arriving at hyperbolic tapering on their own, out of necessity, before the pharmacological explanation for why it worked was published.
Reported in MindSite News, 2025
In its 2020 review of benzodiazepine safety, the FDA examined 104 reported cases. Physical dependence had developed after a median of about two weeks of use. The median duration of withdrawal symptoms was approximately nine and a half months. In the longest case in the series, symptoms had persisted for eight years and were still ongoing at the time of the report.
U.S. Food and Drug Administration, 2020
The other side of this
Some psychiatrists have raised legitimate concern that coverage of withdrawal may frighten people away from treatment that would genuinely help them, or lead someone to stop a medication that is holding them steady. That concern deserves respect.
Nothing on this page argues that psychiatric medication is bad, or that you should come off yours. Many people are alive and well because of these medications, and staying on one is a completely legitimate choice. The argument here is narrower and, I think, uncontroversial: if and when someone does come off, the pace should be set by their nervous system rather than by the tablet sizes the manufacturer happened to produce.
Three people, one plan
Medication changes go best when the people involved are talking to each other rather than each holding one piece.
Your prescriber
Decides whether, when, and how fast. Ask directly:
- What size steps, and how long at each?
- Can we use proportional rather than equal reductions?
- What do we do if symptoms appear — pause, or step back up?
- How will we tell withdrawal from relapse?
Your pharmacist
Knows what is physically obtainable. Ask:
- What strengths does this come in?
- Is there a liquid form?
- Can this tablet be safely split?
- Is there a compounding pharmacy that could make intermediate doses?
- What will insurance cover?
Your therapist
Watches the week-to-week picture. Contributes:
- Detailed observation of your baseline
- Early detection of change
- Withdrawal-versus-relapse perspective
- Support through the hard stretches
- Communication back to your prescriber, with your consent
Sign a release before you start
A signed release of information allows your therapist and prescriber to speak directly. It takes five minutes and it is the single most useful thing you can do to make a medication change go smoothly. Without it, each of us is working from a partial picture and relying on you to carry information between us during precisely the period when you may be least able to.
A letter to take to your prescriber
Many people find it hard to raise this in a short appointment. Writing it down first helps — you will not forget your questions, and it becomes part of your record.
There are two documents here. The letter is short and plain, and it is the one you hand over. The second is an optional attachment with the research behind the request, written for your prescriber rather than for you. Bring both, or just the letter — whichever feels right.
Document 1 — the letter
Date:
Dear Dr. Smith / NP Jones ,
Thank you for the care you have given me.
I would like to talk with you about lowering my dose of name of medicine and current dose more slowly than we planned.
I am not going to change anything on my own. I will only do what we decide together.
Here is what I have noticed:
Write a few sentences about how you have been feeling. If you have tried lowering the dose before, say what happened.
I have read that going down in smaller steps can make this much easier, especially near the end. I have also read that a pharmacist can sometimes help when the pill sizes do not go small enough. I have attached a short summary about this in case it is useful to you.
Could we please talk about:
- Going more slowly, with smaller steps
- What I should do if I start feeling bad
- Whether a pharmacist could help with in-between doses
I would also like you to be able to talk with my therapist, who sees me regularly and knows how I am doing week to week. I am happy to sign a release so you can.
Thank you for listening.
Sincerely,
your name
your phone or email
Document 2 — the attachment (optional)
You do not need to read or understand this one. It is written for your prescriber, and it explains the research behind what you are asking for.
Provided at the request of the patient named in the accompanying letter.
Compiled by Dr. Darleen Claire Wodzenski, MS ESE, MA CMHC, PhD, LPC, ACS, Orchard Human Services, Inc.
Re: Hyperbolic (proportional) tapering, intermediate dosage forms, and stabilisation
This summary accompanies a patient request to discuss a more gradual reduction schedule. It is offered as a courtesy reference and is not a treatment recommendation. A licensed professional counselor does not prescribe or advise on dosing; all clinical decisions rest with the prescribing provider, in consultation with a pharmacist where formulation questions arise.
1. The dose–occupancy relationship is hyperbolic, not linear. Receptor occupancy rises steeply at low doses and plateaus at higher ones. Equal milligram reductions therefore produce progressively larger changes in occupancy as the dose falls, which is why patients frequently tolerate the early steps of a taper and decompensate on the last one. Sørensen et al. (2022) documented this relationship across antidepressants; Horowitz and Taylor (2019) set out the tapering implications.
2. Proportional reduction produces a linear decline in occupancy. Reducing by a percentage of the current dose — rather than by a fixed increment — keeps each step roughly equivalent in pharmacodynamic terms. NICE now recommends proportional reductions in both NG215 and NG222 (National Institute for Health and Care Excellence, 2022a, 2022b).
3. Outcome data. Groot and van Os (2021) followed 824 patients using tapering strips; 72% discontinued successfully over a median of 56 days, despite a median five to ten years of prior use and 71% having previously failed at least one discontinuation attempt. Median self-rated withdrawal severity fell from 6/7 in prior attempts to 3/7. Duration of use was the most consistently replicated predictor of difficulty (78% success under one year; 59% beyond ten years). Notably, elimination half-life did not predict severity — fluoxetine produced a median severity equivalent to paroxetine and venlafaxine.
4. Withdrawal incidence. Davies and Read (2019) found that approximately half of patients discontinuing antidepressants experience withdrawal effects, with roughly half of those rating them severe. Chouinard and Chouinard (2015) distinguish new withdrawal symptoms, rebound, and persistent post-withdrawal disorder — a classification that assists in differentiating withdrawal from relapse.
5. Distinguishing withdrawal from relapse. Onset within days of a dose change, novel somatic features (dizziness, paraesthesia, nausea, flu-like symptoms), symptoms outside the patient’s established illness pattern, and rapid resolution on dose reinstatement all favour withdrawal (Horowitz & Taylor, 2022). Guy et al. (2020) document that patients reporting withdrawal are frequently misattributed to relapse or investigated for unrelated conditions.
6. Secondary effects on sleep and nutrition. Withdrawal commonly disrupts sleep and oral intake. Both independently generate psychiatric symptomatology: sustained sleep deprivation produces perceptual disturbance progressing toward psychosis in individuals without psychiatric history (Waters et al., 2018), and undernutrition reliably produces depressive and obsessional features (Keys et al., 1950). A patient may therefore present with symptoms attributable to withdrawal, to secondary sleep loss, and to secondary undernutrition simultaneously.
7. Intermediate dosage forms. Where commercially available strengths do not permit adequately small decrements, options may include compounded preparations for a time-limited bridging period, manufactured liquid formulations, tapering strips, or conversion to an immediate-release equivalent permitting finer division. Extended-release, delayed-release, and enteric-coated products are generally unsuitable for division or compounding. Pharmacist consultation is advised.
8. Stabilisation. Holding at the current dose when withdrawal emerges — rather than continuing the reduction or reinstating a prior dose — is a recognised step within a personalised taper (Groot & van Os, 2021).
9. Alternate-day dosing. For agents with short elimination half-lives, alternate-day dosing produces oscillating plasma concentrations rather than a steady reduction and has been modelled as increasing withdrawal severity (Horowitz et al., 2025).
10. Collateral observation. The patient is engaged in regular psychotherapy. With the patient’s written consent, the treating counselor can provide week-to-week observational data on sleep, oral intake, functioning, and symptom onset relative to dose changes — information that may assist in differentiating withdrawal from relapse.
References
Chouinard, G., & Chouinard, V.-A. (2015). New classification of selective serotonin reuptake inhibitor withdrawal. Psychotherapy and Psychosomatics, 84(2), 63–71.
Davies, J., & Read, J. (2019). A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors, 97, 111–121.
Groot, P. C., & van Os, J. (2021). Successful use of tapering strips for hyperbolic reduction of antidepressant dose: A cohort study. Therapeutic Advances in Psychopharmacology, 11, 1–13. https://doi.org/10.1177/20451253211039327
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020). The ‘patient voice’: Patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Therapeutic Advances in Psychopharmacology, 10, 1–14.
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2025). Alternate-day dosing to taper antidepressants risks severe withdrawal effects: An in silico analysis. Journal of Affective Disorders.
Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry, 6(6), 538–546.
Horowitz, M. A., & Taylor, D. (2022). Distinguishing relapse from antidepressant withdrawal. BJPsych Advances, 28(5), 297–311.
Horowitz, M. A., & Taylor, D. (2024). The Maudsley deprescribing guidelines. Wiley.
Keys, A., Brožek, J., Henschel, A., Mickelsen, O., & Taylor, H. L. (1950). The biology of human starvation. University of Minnesota Press.
National Institute for Health and Care Excellence. (2022a). Depression in adults: Treatment and management (NG222).
National Institute for Health and Care Excellence. (2022b). Medicines associated with dependence or withdrawal symptoms (NG215).
Sørensen, A., Ruhé, H. G., & Munkholm, K. (2022). The relationship between dose and serotonin transporter occupancy of antidepressants. Molecular Psychiatry, 27, 192–201.
Waters, F., Chiu, V., Atkinson, A., & Blom, J. D. (2018). Severe sleep deprivation causes hallucinations and a gradual progression toward psychosis with increasing time awake. Frontiers in Psychiatry, 9, 303.
- Send them ahead through the patient portal if your office has one. That gives your prescriber time to think.
- Bring printed copies too, and keep one for yourself.
- Change the letter freely. Cut anything that does not fit. A letter that sounds like you will land better than one that sounds like a form.
- The attachment is optional. Some providers will welcome it; others will not need it. Handing it over is not a challenge to their expertise, and it is fine to leave it in your bag.
- If your prescriber disagrees, ask why. There may be good reasons specific to your medicine.
Planned elevated support during a taper
When a client is reducing a medication that has been holding them steady, ordinary therapy spacing is often not enough. The difficult stretches do not schedule themselves conveniently, and the periods just after each reduction are when close observation matters most.
For clients coming off stabilizing medication, I offer a deliberately intensified level of support, arranged in advance rather than assembled in a crisis, and sustained for the full duration of the reduction — not just for the week after each step down.
What that looks like varies with the person and the medication. It has included daily check-ins during the harder stretches, more frequent sessions than a client would otherwise need, structured tracking so that changes are documented rather than remembered, and direct coordination with the prescriber where the client has consented to it.
Where it is useful, I also draw on the rest of the team. I may assign another Orchard staff member to provide ancillary support — someone checking in between sessions, holding continuity when I am not available, and adding a second set of eyes on how the person is actually doing. Tapering can be a long process, and the support should not depend entirely on one person’s calendar.
Two things I want to be clear about. I do not prescribe, and I do not advise anyone on dosing — that is your physician’s role and I will not step into it. What I can do is help you notice what is happening early, help you describe it accurately to the people who do prescribe, and stay close while your nervous system does something genuinely difficult.
- A plan made before the first reduction — what we watch for, how we’ll track it, and what triggers a call to your prescriber.
- Daily check-ins during the periods that warrant them, scaling back as things settle.
- Increased session frequency for the duration of the reduction, not only in the days following each step.
- Ancillary support from another team member where that helps — continuity between sessions and a second perspective on how you are doing.
- Symptom tracking that distinguishes new symptoms from familiar ones, so the withdrawal-versus-relapse question has actual data behind it.
- Deliberate attention to sleep and food intake throughout the taper, treated as clinical priorities rather than lifestyle advice — because when those break down, they generate psychiatric symptoms of their own.
- Coordination with your prescriber and pharmacist, with your written consent.
- Support for the people around you, who often notice changes first and rarely know what to do with what they see.
The curve behind all of this
You do not need this to understand the page. It is here for anyone who wants to see why a small reduction near the end can feel so much larger than a big one near the start.
References
- Baldessarini, R. J., Tondo, L., Faedda, G. L., Suppes, T. R., Floris, G., & Rudas, N. (1996). Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. Journal of Clinical Psychiatry, 57(10), 441–448.
- Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019). Effects of treatment discontinuation in clinical psychopharmacology. Psychotherapy and Psychosomatics, 88(2), 65–70.
- Carey, B., & Gebeloff, R. (2018, April 7). Many people taking antidepressants discover they cannot quit. The New York Times.
- Chouinard, G., & Chouinard, V.-A. (2015). New classification of selective serotonin reuptake inhibitor withdrawal. Psychotherapy and Psychosomatics, 84(2), 63–71.
- Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017). Antipsychotic-induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychotherapy and Psychosomatics, 86(4), 189–219.
- Davies, J., & Read, J. (2019). A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors, 97, 111–121.
- Frank, E., Kupfer, D. J., Thase, M. E., Mallinger, A. G., Swartz, H. A., Fagiolini, A. M., Grochocinski, V., Houck, P., Scott, J., Thompson, W., & Monk, T. (2005). Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Archives of General Psychiatry, 62(9), 996–1004. https://doi.org/10.1001/archpsyc.62.9.996
- Groot, P. C., & van Os, J. (2020). Outcome of antidepressant drug discontinuation with tapering strips after 1–5 years. Therapeutic Advances in Psychopharmacology, 10, 1–9. https://doi.org/10.1177/2045125320954609
- Groot, P. C., & van Os, J. (2021). Successful use of tapering strips for hyperbolic reduction of antidepressant dose: A cohort study. Therapeutic Advances in Psychopharmacology, 11, 1–13. https://doi.org/10.1177/20451253211039327
- Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020). The ‘patient voice’: Patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Therapeutic Advances in Psychopharmacology, 10, 1–14. https://doi.org/10.1177/2045125320967183
- Harvey, A. G. (2008). Sleep and circadian rhythms in bipolar disorder: Seeking synchrony, harmony, and regulation. American Journal of Psychiatry, 165(7), 820–829. https://doi.org/10.1176/appi.ajp.2008.08010098
- Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2025). Alternate-day dosing to taper antidepressants risks severe withdrawal effects: An in silico analysis. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120084
- Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021). A method for tapering antipsychotic treatment that may minimize the risk of relapse. Schizophrenia Bulletin, 47(4), 1116–1129.
- Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry, 6(6), 538–546. https://doi.org/10.1016/S2215-0366(19)30032-X
- Horowitz, M. A., & Taylor, D. (2022). Distinguishing relapse from antidepressant withdrawal: Clinical practice and antidepressant discontinuation studies. BJPsych Advances, 28(5), 297–311.
- Horowitz, M. A., & Taylor, D. (2024). The Maudsley deprescribing guidelines: Antidepressants, benzodiazepines, gabapentinoids and Z-drugs. Wiley.
- Howland, R. H. (2010). Potential adverse effects of discontinuing psychotropic drugs. Part 3: Antipsychotic, dopaminergic, and mood-stabilizing drugs. Journal of Psychosocial Nursing and Mental Health Services, 48(8), 11–14.
- Jacka, F. N., O’Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., Castle, D., Dash, S., Mihalopoulos, C., Chatterton, M. L., Brazionis, L., Dean, O. M., Hodge, A. M., & Berk, M. (2017). A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Medicine, 15, 23. https://doi.org/10.1186/s12916-017-0791-y
- Keys, A., Brožek, J., Henschel, A., Mickelsen, O., & Taylor, H. L. (1950). The biology of human starvation (Vols. 1–2). University of Minnesota Press.
- Moncrieff, J. (2006). Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica, 114(1), 3–13.
- National Institute for Health and Care Excellence. (2022a). Depression in adults: Treatment and management (NICE Guideline NG222).
- National Institute for Health and Care Excellence. (2022b). Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management (NICE Guideline NG215).
- The New York Times. (2018, April 20). Antidepressants and withdrawal: Readers tell their stories.
- Read, J., Renton, J., Harrop, C., Geekie, J., & Dowrick, C. (2020). A survey of UK general practitioners about depression, antidepressants and withdrawal: Implementing the 2019 Public Health England report. Therapeutic Advances in Psychopharmacology, 10, 1–10. https://doi.org/10.1177/2045125320950124
- Schuch, F. B., Vancampfort, D., Richards, J., Rosenbaum, S., Ward, P. B., & Stubbs, B. (2016). Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research, 77, 42–51. https://doi.org/10.1016/j.jpsychires.2016.02.023
- Sørensen, A., Ruhé, H. G., & Munkholm, K. (2022). The relationship between dose and serotonin transporter occupancy of antidepressants — A systematic review. Molecular Psychiatry, 27, 192–201.
- U.S. Food and Drug Administration. (2020, September 23). FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. FDA Drug Safety Communication.
- Waters, F., Chiu, V., Atkinson, A., & Blom, J. D. (2018). Severe sleep deprivation causes hallucinations and a gradual progression toward psychosis with increasing time awake. Frontiers in Psychiatry, 9, 303. https://doi.org/10.3389/fpsyt.2018.00303
- Wehr, T. A., Sack, D. A., & Rosenthal, N. E. (1987). Sleep reduction as a final common pathway in the genesis of mania. American Journal of Psychiatry, 144(2), 201–204. https://doi.org/10.1176/ajp.144.2.201
Would you like support through this? Request a consult.
Dr. Darleen Claire Wodzenski, MS ESE, MA CMHC, PhD, LPC, ACS · Orchard Human Services, Inc.
This page is educational and does not constitute medical advice, diagnosis, or treatment for any individual. It is not a tapering protocol. Licensed professional counselors do not prescribe or advise on medication dosing. Always consult your prescribing physician and pharmacist before making any change to a psychiatric medication.
If you are in crisis, call or text 988. For a medical emergency, call 911.